SBIR/STTR Research Award
Vaccine enhancement through antigen targeting
Award amount
$104,000Program and phase
SBIR · Phase IAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Iterative Therapeutics Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NKKKLM6NKF39
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): There is currently a great need for new and more effective vaccines. Vaccines based on recombinant proteins, purified subunits, or peptides often elicit poor immune responses resulting in a failure to achieve vacc
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Enhanced NK cell activation via Fc receptor ligand cytokine combinations
- Rapid Response Vaccines for Botulinum Neurotoxins
- Novel HER2 targeting immunotherapeutics for breast cancer
Research funding history
4 SBIR/STTR records share this UEI (2004–2017). Reported award amounts total $1,347,807. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services